BioCentury
ARTICLE | Company News

Otsuka Pharmaceutical sales and marketing update

November 9, 2015 8:00 AM UTC

The U.K.’s NICE issued final guidance recommending Jinarc tolvaptan from Otsuka to treat autosomal dominant polycystic kidney disease (ADPKD). The vasopressin 2 (V2) receptor antagonist is recommend...